🇪🇺 Bromfenac 0.09 % Ophthalmic Solution in European Union

EMA authorised Bromfenac 0.09 % Ophthalmic Solution on 18 May 2011

Marketing authorisation

EMA — authorised 18 May 2011

  • Application: EMEA/H/C/001198
  • Marketing authorisation holder: Bausch + Lomb Ireland Limited
  • Local brand name: Yellox
  • Indication: Treatment of postoperative ocular inflammation following cataract extraction in adults.
  • Status: approved

Read official source →

Other Ophthalmology approved in European Union

Frequently asked questions

Is Bromfenac 0.09 % Ophthalmic Solution approved in European Union?

Yes. EMA authorised it on 18 May 2011.

Who is the marketing authorisation holder for Bromfenac 0.09 % Ophthalmic Solution in European Union?

Bausch + Lomb Ireland Limited holds the EU marketing authorisation.